See the published version of this preprint at Nature Medicine.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Brief Communication
Samra Turajlic
Francis Crick Institute
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8846-136X
License:
This work is licensed under a CC BY 4.0 License. Read Full License
We present a case of cytokine release syndrome (CRS) that occurred five days after vaccination with BTN162b2 (tozinameran), an mRNA COVID-19 vaccine, in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-y/IL-2R/IL-18/IL-16/IL-10), and steroid responsiveness.
Keywords
cytokine release syndrome (CRS), mRNA vaccine, immunology
Figure 1
Figure 2
Yes there is potential Competing Interest. L.A. is funded by the Royal Marsden Cancer Charity. A.F. has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 892360. M.C., K.A.W. and R.J.W. receives core funding from the Francis Crick Institute (FC001218). J.S. and W.H. are employees and shareholders at Serimmune Inc. N.J-H receives funding from Cancer Research UK (grant reference number C65320/A26413). J.L. has worked in a consulting or advisory role for Achilles Therapeutics, AstraZeneca, Boston Biomedical, Bristol Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Imugene, Incyte, iOnctura, Ipsen, Kymab, Merck Serono, Merck Sharp & Dohme, Nektar Therapeutics, Novartis, Pierre Fabre, Pfizer, Roche/Genetech, Secarna, and Vitaccess; and has received support from NIHR RM/ICR Biomedical Research Centre for Cancer, and institutional research support from Achilles Therapeutics, Aveo, Bristol Myers Squibb, Covance, Immunocore, Merck Sharp & Dohme, Nektar Therapeutics, Novartis, Pharmacyclics, Pfizer, and Roche. D.L. is the recipient of the Australasian Gastro-Intestinal Trials Group/Merck Clinical Research Fellowship. I.C. has worked in a consulting or advisory role for Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics, Astra-Zeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte, and Astella; and has received research funding from Eli-Lilly and Janssen-Cilag; and has received honorarium from Eli-Lilly and Eisai. S.T. has received speaking fees from Roche, Astra Zeneca, Novartis and Ipsen. G.K. receives core funding from the Francis Crick Institute (FC0010099). S.T. is funded by Cancer Research UK (grant reference number C50947/A18176), the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC0010988), the UK Medical Research Council (FC0010988), and the Wellcome Trust (FC0010988), the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research (grant reference number A109), the Royal Marsden Cancer Charity, The Rosetrees Trust (grant reference number A2204), Ventana Medical Systems Inc (grant reference numbers 10467 and 10530), the National Institute of Health (Bethesda) and Melanoma Research Alliance. All other authors declare no conflicts of interest.
This is a list of supplementary files associated with this preprint. Click to download.
- CRSsupplTurajlic.docx
Supplemental Material
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Nature Medicine.
Version 1
Posted 30 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Immunology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Nature Medicine.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Brief Communication
Samra Turajlic
Francis Crick Institute
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8846-136X
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Nature Medicine.
Version 1
Posted 30 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Immunology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Nature Medicine.
We present a case of cytokine release syndrome (CRS) that occurred five days after vaccination with BTN162b2 (tozinameran), an mRNA COVID-19 vaccine, in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-y/IL-2R/IL-18/IL-16/IL-10), and steroid responsiveness.
Figure 1
Figure 2
Yes there is potential Competing Interest. L.A. is funded by the Royal Marsden Cancer Charity. A.F. has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 892360. M.C., K.A.W. and R.J.W. receives core funding from the Francis Crick Institute (FC001218). J.S. and W.H. are employees and shareholders at Serimmune Inc. N.J-H receives funding from Cancer Research UK (grant reference number C65320/A26413). J.L. has worked in a consulting or advisory role for Achilles Therapeutics, AstraZeneca, Boston Biomedical, Bristol Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Imugene, Incyte, iOnctura, Ipsen, Kymab, Merck Serono, Merck Sharp & Dohme, Nektar Therapeutics, Novartis, Pierre Fabre, Pfizer, Roche/Genetech, Secarna, and Vitaccess; and has received support from NIHR RM/ICR Biomedical Research Centre for Cancer, and institutional research support from Achilles Therapeutics, Aveo, Bristol Myers Squibb, Covance, Immunocore, Merck Sharp & Dohme, Nektar Therapeutics, Novartis, Pharmacyclics, Pfizer, and Roche. D.L. is the recipient of the Australasian Gastro-Intestinal Trials Group/Merck Clinical Research Fellowship. I.C. has worked in a consulting or advisory role for Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics, Astra-Zeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte, and Astella; and has received research funding from Eli-Lilly and Janssen-Cilag; and has received honorarium from Eli-Lilly and Eisai. S.T. has received speaking fees from Roche, Astra Zeneca, Novartis and Ipsen. G.K. receives core funding from the Francis Crick Institute (FC0010099). S.T. is funded by Cancer Research UK (grant reference number C50947/A18176), the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC0010988), the UK Medical Research Council (FC0010988), and the Wellcome Trust (FC0010988), the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research (grant reference number A109), the Royal Marsden Cancer Charity, The Rosetrees Trust (grant reference number A2204), Ventana Medical Systems Inc (grant reference numbers 10467 and 10530), the National Institute of Health (Bethesda) and Melanoma Research Alliance. All other authors declare no conflicts of interest.
This is a list of supplementary files associated with this preprint. Click to download.
- CRSsupplTurajlic.docx
Supplemental Material
Loading...